ATE308335T1 - Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese - Google Patents
Histidine-rich glycoprotein (hrgp) zur hemmung der angiogeneseInfo
- Publication number
- ATE308335T1 ATE308335T1 AT02733167T AT02733167T ATE308335T1 AT E308335 T1 ATE308335 T1 AT E308335T1 AT 02733167 T AT02733167 T AT 02733167T AT 02733167 T AT02733167 T AT 02733167T AT E308335 T1 ATE308335 T1 AT E308335T1
- Authority
- AT
- Austria
- Prior art keywords
- hrgp
- histidine
- polypeptides
- rich glycoprotein
- inhibit angiogenesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26650501P | 2001-02-05 | 2001-02-05 | |
PCT/IB2002/002425 WO2002076486A2 (en) | 2001-02-05 | 2002-02-04 | Histidine-rich glycoprotein |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE308335T1 true ATE308335T1 (de) | 2005-11-15 |
Family
ID=23014841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02733167T ATE308335T1 (de) | 2001-02-05 | 2002-02-04 | Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese |
Country Status (8)
Country | Link |
---|---|
US (2) | US7205392B2 (de) |
EP (1) | EP1357930B1 (de) |
JP (1) | JP2004527242A (de) |
AT (1) | ATE308335T1 (de) |
CA (1) | CA2436340A1 (de) |
DE (1) | DE60207043T2 (de) |
ES (1) | ES2252461T3 (de) |
WO (1) | WO2002076486A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002076486A2 (en) | 2001-02-05 | 2002-10-03 | Innoventus Project Ab | Histidine-rich glycoprotein |
JP2005528879A (ja) * | 2001-02-14 | 2005-09-29 | アテニュオン, エルエルシー | 抗脈管形成剤および抗腫瘍剤としてのヒスチジンプロリンリッチ糖タンパク質(hprg) |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
SE0301988D0 (sv) | 2003-07-07 | 2003-07-07 | Innoventus Project Ab | Active subfragment of an endogenous peptide |
CN102895663A (zh) | 2004-04-14 | 2013-01-30 | 健泰科生物技术公司 | 含有用于调节血管发育的egfl7拮抗剂的组合物及方法 |
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
CN103189748A (zh) * | 2010-04-01 | 2013-07-03 | 卡罗林斯卡学院创新有限公司 | 授精预测和促进 |
MX359314B (es) | 2011-08-30 | 2018-09-25 | Astex Pharmaceuticals Inc Star | Formulaciones derivadas de decitabina. |
US9696321B2 (en) | 2012-06-06 | 2017-07-04 | National University Corporation Okayama University | Therapeutic agent, method of treatment and method for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused or accompanied by neutrophil activation |
WO2013183494A1 (ja) | 2012-06-06 | 2013-12-12 | 国立大学法人 岡山大学 | 好中球活性化に起因する疾患の治療薬、治療方法及び検査方法 |
RU2723590C2 (ru) | 2015-07-02 | 2020-06-16 | Оцука Фармасьютикал Ко., Лтд. | Лиофилизированные фармацевтические композиции |
KR20200035438A (ko) | 2017-08-03 | 2020-04-03 | 오쓰까 세이야꾸 가부시키가이샤 | 약물 화합물 및 이의 정제 방법 |
JPWO2019230509A1 (ja) | 2018-05-31 | 2021-06-24 | 国立大学法人 岡山大学 | 活性酸素の産生抑制剤及び/又は消去促進剤 |
EP3815706A4 (de) | 2018-06-28 | 2022-03-16 | National University Corporation Okayama University | Mittel zur verbesserung der phagozytosefähigkeit von neutrophilen |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5133866A (en) | 1988-03-24 | 1992-07-28 | Terrapin Technologies, Inc. | Method to identify analyte-bending ligands |
JPH0753757B2 (ja) * | 1988-08-12 | 1995-06-07 | 寳酒造株式会社 | モノクローナル抗体及びその使用方法 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (de) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
US5994309A (en) | 1997-07-25 | 1999-11-30 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods |
AU780730B2 (en) | 1999-10-01 | 2005-04-14 | Angstrom Pharmaceuticals, Inc. | Diagnostic probes and therapeutics targeting uPA and uPAR |
US20010041670A1 (en) * | 1999-12-06 | 2001-11-15 | Ronit Simantov | Thrombospondin-binding region of histidine-rich glycoprotein and method of use |
AU2001227679A1 (en) | 2000-02-25 | 2001-09-03 | General Atomics | Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods |
JP2004515222A (ja) | 2000-07-24 | 2004-05-27 | アテニュオン, エルエルシー | ヒトキニノゲンd5ドメインポリペプチドおよびこれらの使用 |
WO2002069885A2 (en) | 2001-01-19 | 2002-09-12 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods for treating brain tumors and other diseases |
WO2002076486A2 (en) | 2001-02-05 | 2002-10-03 | Innoventus Project Ab | Histidine-rich glycoprotein |
JP2005528879A (ja) | 2001-02-14 | 2005-09-29 | アテニュオン, エルエルシー | 抗脈管形成剤および抗腫瘍剤としてのヒスチジンプロリンリッチ糖タンパク質(hprg) |
-
2002
- 2002-02-04 WO PCT/IB2002/002425 patent/WO2002076486A2/en active IP Right Grant
- 2002-02-04 US US10/067,093 patent/US7205392B2/en not_active Expired - Fee Related
- 2002-02-04 CA CA002436340A patent/CA2436340A1/en not_active Abandoned
- 2002-02-04 ES ES02733167T patent/ES2252461T3/es not_active Expired - Lifetime
- 2002-02-04 AT AT02733167T patent/ATE308335T1/de not_active IP Right Cessation
- 2002-02-04 EP EP02733167A patent/EP1357930B1/de not_active Expired - Lifetime
- 2002-02-04 DE DE60207043T patent/DE60207043T2/de not_active Expired - Fee Related
- 2002-02-04 JP JP2002574999A patent/JP2004527242A/ja active Pending
-
2004
- 2004-09-27 US US10/951,059 patent/US7563765B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002076486A3 (en) | 2003-04-17 |
US20050042201A1 (en) | 2005-02-24 |
CA2436340A1 (en) | 2002-10-03 |
JP2004527242A (ja) | 2004-09-09 |
ES2252461T3 (es) | 2006-05-16 |
US7205392B2 (en) | 2007-04-17 |
EP1357930B1 (de) | 2005-11-02 |
DE60207043T2 (de) | 2006-07-13 |
US7563765B2 (en) | 2009-07-21 |
DE60207043D1 (de) | 2005-12-08 |
WO2002076486A2 (en) | 2002-10-03 |
US20020165131A1 (en) | 2002-11-07 |
EP1357930A2 (de) | 2003-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE308335T1 (de) | Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese | |
HK1088840A1 (en) | Stable analogs of glp-1 glp-1 | |
DK1129190T3 (da) | Human TSLP DNA og polypeptider | |
CY1113421T1 (el) | Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα | |
DE69926480D1 (de) | Acpl dna und polypeptide | |
NO20063026L (no) | Antistoffer | |
HRP20050024A2 (en) | Pegylated t20 polypeptide | |
NO20062385L (no) | Preparat for behandling av interferonresistente tumorer | |
DK1461073T3 (da) | Peptidagonister til prostataspecifikt antigen og anvendelser heraf | |
MX2020013296A (es) | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. | |
NO20060675L (no) | Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider | |
DE60118359D1 (de) | Humanische pellino-polypeptide | |
DE60214676D1 (de) | Hochaffine antagonisten der elr-cxc chemokine | |
DE60219215D1 (de) | Prionen-bindende peptidsequenzen | |
ATE387629T1 (de) | Gemeinsame epitope von antigenen aus einer multigen-familie | |
MXPA04004564A (es) | Genes que codifican receptores acoplados a proteinas g y metodos de uso de los mismos. | |
NO331197B1 (no) | Fremgangsmate for a identifisere forbindelser som binder til EDG8-polypeptid | |
CA2380216A1 (en) | Use of interleukin-18 inhibitors to inhibit tumor metastasis | |
DK1183362T3 (da) | IL-1- ETA-DNA og -polypeptider | |
ATE441865T1 (de) | Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila | |
ATE442444T1 (de) | Glykosylphosphatidylinositolhaltige polypeptide | |
ATE443715T1 (de) | Polypeptide aus haemophilus influenza | |
DE60039303D1 (de) | Immunogene polypeptide aus moraxella catarrhalis und deren verwendungen | |
DE10394174D2 (de) | Peptide mit hohem Cysteingehalt | |
AU2003260546A8 (en) | Device for the presentation of peptides or proteins, method for the preparation and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |